https://orcid.org/0000-0003-3125-2262
References
- Hum J, Jou JH, Green PK, et al. Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care. 2017;40(9):1173–1180.
- Luo A, Xu P, Wang J, et al. Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis. Medicine (Baltimore). 2019;98(20):e15626.
- Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–576.
- Rosenberg ES, Barocas JA. USPSTF’s hepatitis C screening recommendation-a necessary step to tackling an evolving epidemic. JAMA Network Open. 2020;3(3):e200538.
- Tran TT. Hepatitis C: who should treat hepatitis C virus? The role of the primary care provider. Clin Liver Dis. 2018;11(3):66–68.
- Ghany MG, Morgan TR. AASLD-IDSA hepatitis C guidance panel. Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721.